Veradigm Stock Price, News & Analysis

Allscripts Healthcare Solutions (MDRX) reported a 10% increase in year-to-date bookings, totaling $172 million. The second quarter of 2022 saw revenues of $151 million, up from $141 million in 2021. Veradigm's revenue rose to $145 million, a gain from $133 million YoY. Despite a GAAP loss from operations of $5 million, adjusted EBITDA improved to $39 million. The company affirms its financial outlook for 2022, projecting 6-7% revenue growth and free cash flow between $110-120 million. Stock repurchases amounted to $94 million in Q2.

Allscripts Healthcare Solutions (NASDAQ: MDRX) is set to report its financial results for Q2 2022 on August 4, 2022, after market close. The announcement will include details on the earnings call scheduled for 4:30 PM ET the same day. The earnings announcement will be available on Allscripts' investor relations website. Investors can join the call via phone or through the website. A replay will be accessible for six months post-call.

Pulse8 has announced that its Qualit8 solution achieved MY2022 Measure Certification from the National Committee for Quality Assurance (NCQA) for the third consecutive year. This certification highlights the solution’s commitment to enhancing administrative efficiency and delivering value to health plan customers. The NCQA-Certified HEDIS Measurement Program offers various certifications, including Health Plan Measures and Hybrid Sampling. Veradigm's dedication to transparent analytics aims to reduce healthcare spending and waste while improving efficiency for its clients.

Veradigm, a unit of Allscripts Healthcare Solutions (NASDAQ: MDRX), has received a patent for its innovative "Dynamic Intervention Planning" method. This system enhances risk adjustment programs by enabling clients to identify, assess, and prioritize opportunities effectively. According to Tom Langan, the company aims to reduce waste and improve accuracy in revenue predictions, thereby allowing better management of client programs. Veradigm uniquely positions itself in the market by controlling significant aspects of risk adjustment, which can lead to greater financial returns for health plans.

Allscripts (MDRX) announced that researchers from Veradigm will present health economics and outcomes research data on Covid-19, diabetes, NASH, and cardiovascular disease at ISPOR 2022 in Washington, D.C., from May 15-18, 2022. Key presentations will focus on real-world data to improve public health initiatives, including the Covid-19 Dashboard to guide outreach to underserved communities. Veradigm aims to harness diverse data sources for better clinical outcomes and decision-making. This research could enhance understanding of disease risk factors and public health response.

On May 5, 2022, Allscripts Healthcare Solutions (MDRX) announced its Q1 2022 financial results, revealing a GAAP diluted EPS of $0.17 and a non-GAAP diluted EPS of $0.13. The company generated $35 million in cash flow from continuing operations and reported Veradigm revenue of $136 million, up from $126 million in Q1 2021. Consolidated GAAP net income reached $23 million, a significant increase from $9 million last year. The company confirmed its annual outlook, expecting Veradigm revenue growth of 6% to 7% and adjusted EBITDA growth of 10% to 15%.

Allscripts Healthcare Solutions (NASDAQ:MDRX) has finalized the sale of its Hospital and Large Physician Practices business to Constellation Software Inc.'s subsidiary, N. Harris Computer Corporation. This strategic move aims to enhance Allscripts' focus on high-growth markets, thereby providing greater value to clients, employees, and shareholders, according to President and CFO Rick Poulton. The transition also includes potential risks related to earnings and management attention diversions, reflecting on Allscripts' future performance expectations.

Allscripts Healthcare Solutions (NASDAQ:MDRX) will release its financial results for Q1 2022 on May 5, 2022, after market close. The earnings announcement will be followed by a conference call at 4:30 p.m. Eastern Time to discuss the results. Interested participants can access the call through the Allscripts Investor Relations website or by dialing 877-269-7756. A replay will be available for four weeks post-call. Allscripts specializes in healthcare information technology solutions aimed at improving clinical and operational outcomes.

Allscripts (NASDAQ: MDRX) has relaunched its Application Store, now called the Allscripts App Expo, enhancing accessibility for clients to discover certified applications developed through the Allscripts Developer Program. The platform expands the visibility of certified solutions built with Allscripts APIs, promoting interoperability. Allscripts continues to support connectivity across various environments and specialties, with hundreds of certified apps available. The company’s commitment to innovation is evidenced by participation in upcoming industry events, including ViVE 2022 and HIMSS 2022.